Merck & Co., Inc. (NYSE:MRK) – Cantor Fitzgerald increased their FY2019 EPS estimates for shares of Merck & Co., Inc. in a research note issued on Wednesday, May 1st, according to Zacks Investment Research. Cantor Fitzgerald analyst L. Chen now expects that the company will earn $4.70 per share for the year, up from their prior estimate of $4.57. Cantor Fitzgerald has a “Buy” rating and a $95.00 price objective on the stock.
A number of other analysts have also recently issued reports on the company. Atlantic Securities raised Merck & Co., Inc. from a “neutral” rating to an “overweight” rating in a report on Monday, May 13th. They noted that the move was a valuation call. ValuEngine raised Merck & Co., Inc. from a “hold” rating to a “buy” rating in a report on Friday, May 3rd. UBS Group raised their price target on Merck & Co., Inc. from $87.00 to $88.00 and gave the company a “buy” rating in a report on Thursday, May 2nd. Bank of America raised their price target on Merck & Co., Inc. from $90.00 to $91.00 and gave the company a “buy” rating in a report on Wednesday, May 1st. Finally, BMO Capital Markets raised their price target on Merck & Co., Inc. from $83.00 to $84.00 and gave the company a “market perform” rating in a report on Wednesday, May 1st. Three equities research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the stock. Merck & Co., Inc. currently has a consensus rating of “Buy” and a consensus price target of $82.92.
Merck & Co., Inc. (NYSE:MRK) last issued its quarterly earnings data on Tuesday, April 30th. The company reported $1.22 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.05 by $0.17. The business had revenue of $10.82 billion for the quarter, compared to analysts’ expectations of $10.45 billion. Merck & Co., Inc. had a return on equity of 39.85% and a net margin of 19.50%. The firm’s quarterly revenue was up 7.8% on a year-over-year basis. During the same quarter in the prior year, the firm posted $1.05 EPS.
Institutional investors have recently made changes to their positions in the company. C J Advisory Inc bought a new position in Merck & Co., Inc. during the 1st quarter worth approximately $32,000. WP Advisors LLC bought a new position in Merck & Co., Inc. during the 1st quarter worth approximately $36,000. Brand Asset Management Group Inc. bought a new stake in shares of Merck & Co., Inc. in the 1st quarter worth approximately $37,000. C M Bidwell & Associates Ltd. bought a new stake in shares of Merck & Co., Inc. in the 1st quarter worth approximately $38,000. Finally, PRW Wealth Management LLC bought a new stake in shares of Merck & Co., Inc. in the 4th quarter worth approximately $41,000. Hedge funds and other institutional investors own 73.85% of the company’s stock.
In other news, Chairman Kenneth C. Frazier sold 135,613 shares of the stock in a transaction dated Tuesday, February 19th. The stock was sold at an average price of $80.03, for a total transaction of $10,853,108.39. Following the transaction, the chairman now directly owns 784,863 shares in the company, valued at approximately $62,812,585.89. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Kenneth C. Frazier sold 53,961 shares of the stock in a transaction dated Friday, February 22nd. The shares were sold at an average price of $80.02, for a total value of $4,317,959.22. Following the transaction, the chief executive officer now owns 733,942 shares in the company, valued at $58,730,038.84. The disclosure for this sale can be found here. Insiders have sold a total of 673,712 shares of company stock worth $54,776,448 over the last quarter. Corporate insiders own 0.27% of the company’s stock.
About Merck & Co., Inc.
Merck & Co, Inc provides healthcare solutions worldwide. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services, and Alliances. The company offers therapeutic and preventive agents to treat cardiovascular, type 2 diabetes, chronic hepatitis C virus, HIV-1 infection, intra-abdominal, fungal infection, insomnia, and inflammatory diseases.
Featured Story: Derivative
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.